Targeting a specific protein in acute myeloid leukemia with a new treatment approach
Official title: Selective treatment of acute myeloid leukemia with radioimmunotherapies targeting the active conformation of integrin beta-2
Funded at University of California, San Francisco · NIH-11162010 · Data updated 2026-11-12
This study is testing a new treatment for acute myeloid leukemia (AML) that uses a special antibody to target cancer cells, aiming to offer a safer and more effective option for patients who don't have many choices left.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | March 7, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $678,101 |
| NIH project number | 1R01CA297845-01A1 |
| Project ID | NIH-11162010 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia who have not responded well to current therapies.
✕Less likely to help
Patients with other types of leukemia or those who are not diagnosed with acute myeloid leukemia may not benefit from this research.
What this research studies
This research focuses on developing a novel treatment for acute myeloid leukemia (AML) by using a specialized antibody that targets the active form of a protein called integrin beta-2. The approach involves creating a radioimmunotherapy that combines this antibody with a radioactive substance to selectively attack cancer cells. By utilizing advanced proteomic technology, the researchers aim to improve the safety and effectiveness of the treatment compared to existing therapies. This innovative strategy could provide a new option for patients who have limited treatment choices.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment outcomes for patients with acute myeloid leukemia.
How similar studies have gone: Similar approaches using radioimmunotherapy have shown success in treating other cancers, indicating potential for this novel strategy in AML.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Wiita, Arun P. — University of California, San Francisco
- Study coordinator: Wiita, Arun P.
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.